Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05843968
Other study ID # HYang
Secondary ID
Status Recruiting
Phase Phase 2
First received
Last updated
Start date January 29, 2023
Est. completion date July 1, 2026

Study information

Verified date April 2024
Source Children's Hospital of Chongqing Medical University
Contact Yang Haiping, Doctor
Phone 8618983703661
Email oyhp@hospital.cqmu.edu.cn
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The goal of this clinical trial is to evaluate the efficacy and safety of rituximab(RTX) and mycophenolate mofetile(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS).


Description:

Idiopathic nephrotic syndrome(INS) is the most common glomerular disease in childhood. Currently, steroids are the primary treatment, but there are significant steroid-related toxicity, such as growth disorders, behavior changes, obesity, Cushing's syndrome, eye disease, osteoporosis, etc. Both MMF and RTX have been shown to be effective in the treatment of SDNS, and there is a lack of prospective controlled studies to explore the optimal treatment regimen for low-dose SDNS. Therefore, the investigators will conduct a single-center, randomized controlled trial to evaluate the efficacy and safety of twice-daily rituximab(RTX) versus mycophenolate mofetil(MMF) in the treatment of children with low-dose steroid-dependent nephrotic syndrome(SDNS). After the start of the study, all participants will be screened consecutively and eligible participants will be included in the study. Bias of potential influencing factors will be addressed by inclusion as covariates in the statistical analysis. Independent clinical site monitoring to ensure the safety and integrity of clinical data while patients adhere to the study protocol will focus on source data documentation, strict adherence to data correctness and study procedures, such as randomization and treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 46
Est. completion date July 1, 2026
Est. primary completion date July 1, 2026
Accepts healthy volunteers No
Gender All
Age group 3 Years to 16 Years
Eligibility Inclusion Criteria: - Children with a definite diagnosis of SDNS are included in the study during relapse treatment. - Age 3-16 years. - Steroid dependent dose=0.3mg/kg/day. - Cumulative steroid use for =6 months. - Ability to swallow tablet. - Guardians understand the characteristics and personal consequences of clinical trial. - Guardians willing to give informed written consent. Exclusion Criteria: - Diagnosis of secondary NS, such as secondary to lupus nephritis, hepatitis B-related nephritis, purpura nephritis, etc. - Anti-neutrophil cytoplasmic antibodies(ANCA) positive or complement C3 level decreased. - Diagnosis of hereditary nephrotic syndrome. - Full dose of prednisone (2mg/kg/day, maximum 60mg) are used for 14 days after relapse and urine protein don't turn negative. - Estimated glomerular filtration rate (eGFR) <90mL/min per 1.73m^2 at study entry. - Those who with a known allergy to Mycophenolate Mofetil and their excipients or to Rituximab and its excipients. - Those who refuse to participate in the trial. - Those who participate other clinical trials. - Those who with positive HBV serological markers (HBsAg or/and HBeAg or/and HBcAb), HCV positive patients or patients with abnormal liver function (ALT,AST,or bilirubin>2 or more times the upper limit of the normal range and persistently elevated for 2 weeks). - Severe leukopenia (white blood cells<3.0×10^9), severe anemia (hemoglobin<90g/l), and thrombocytopenia (platelets<100×10^9) at study entry. - History of pancreatitis or definite gastrointestinal ulcers and/or gastrointestinal bleeding within 6 months. - Those who with congenital or acquired immune deficiency, or with active tuberculosis, active CMV and other infections. - Those who with other serious physical or mental illnesses. - History of malignant tumor within 5 years. - Those who with congenital heart disease, arrhythmia, heart failure and other serious cardiovascular diseases. - Those who with serious infections requiring intravenous antibiotics.

Study Design


Intervention

Drug:
Rituximab
2 doses of rituximab 375 mg/m^2(maximum 500mg/day) at 6 months intervals. Half an hour before rituximab infusion: oral acetaminophen 15mg/kg, oral or intramuscular antihistamine, methylprednisolone 2mg/kg IV. Trimethoprim-sulfamethoxazole should be administered orally from the initiation of rituximab therapy until peripheral-blood B cell recovery to prevent pneumocystis infection.
Mycophenolate Mofetil
Mycophenolate Mofetil 20-30 mg/kg/day BID,then adjust the dosage of drugs(maximum 2g/day) to maintian the concentration for MPA-AUC is 30-50µg.h/ml. Total duration:1year. Steroids dose:1.5mg/kg(maximum 40mg) qod for 2 weeks and gradually taper by 0.3 mg/kg every 2 weeks

Locations

Country Name City State
China Children's Hospital of Chongqing Medical University Chongqing Chongqing

Sponsors (1)

Lead Sponsor Collaborator
Children's Hospital of Chongqing Medical University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary 12-month relapse-free survival rate The rate of no relapse within 12 months. 12 months
Secondary 6-month relapse-free survival Relapse-free survival within 6 months. 6 months
Secondary 6-month relapse-free survival rate The rate of no relapse within 6 months. 6 months
Secondary 12-month relapse-free survival Relapse-free survival within 12 months. 12 months
Secondary Proportion of frequent relapses The proportion of frequent relapses.Frequent relapsing NS:=2 relapses per 6 months within 6 months of disease onset or =4 relapses per 12 months in any subsequent 12-month period. Months 6,12
Secondary Cumulative steroid dosage The total dosage of steroid from the beginning to the end of the trial. 12 months
Secondary Number of relapses within 0-12,0-6, and 7-12 months Number of relapses within 0-6 months,7-12 months, and total within 0-12 months. 12 months
Secondary Time of first relapse The first time to relapse after patients taking part in this study. 12 months
Secondary Adverse event It is a binary variable(1/0).The varibale would be setted as "1" if any adverse events occours including obesity, hypertrichosis, psychological disorders,glaucoma,neutropenia,hypogammaglobulinemia, rituximab-related lung injury, fatal hepatitis reactivation, multifocal leukoencephalopathy,severe diarrhea, severe infection. Adverse events graded according to Common Terminology Criteria For Adverse Events (CTCAE v4.0) 12 months
Secondary Proportion of participants who discontinued steroids Proportion of participants who discontinued steroids at 12 months 12 months
Secondary Height standard deviation score(SDS) SDS of height at 6 and 12 months, absolute and relative changes in SDS from baseline to 12 months. months 0,6,12
Secondary Body mass index(BMI) Weight and height will be combined to report BMI in kg/m^2. BMI at 6 and 12 months, absolute and relative changes in BMI from baseline to 12 months. Months 0,6,12
Secondary Quality of life score The researchers assess the quality of life of the participants useing Pediatric Quality of Life Inventory (PedsQL). Baseline to 12 months
Secondary Cost of treatment The researchers calculate their cost during the study. 12 months
See also
  Status Clinical Trial Phase
Not yet recruiting NCT05044169 - Efficacy and Safety of Broncho-Vaxom in the First Episode of Pediatric Idiopathic Nephrotic Syndrome N/A
Recruiting NCT05588063 - taVNS for FRNS in Children N/A
Recruiting NCT05583942 - A Pilot Trial of taVNS for SRNS in Children (kidNEY-VNS) N/A
Recruiting NCT06125405 - Study of the Telitacicept in Pediatric Patients With Frequently Relapsing or Steroid Dependent Nephrotic Syndrome Phase 3
Completed NCT04034316 - Reduce Immunosuppression With Atmp in NS ChildrEn Phase 2
Completed NCT04048161 - Study of Tacrolimus vs Mycophenolate Mofetil in Pediatric Patients With Nephrotic Syndrome Phase 4
Recruiting NCT06079788 - Study of Adrenocorticotropic Hormone on Children With Frequent Relapse or Steroid-dependent Nephrotic Syndrome: a Prospective, Multicenter, Randomized,Open-label Clinical Trial. Phase 3
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT06417320 - Effect of Sodium-glucose Cotransporter-2 Inhibitors (SGLT-2i) on Proteinuria in Nephrotic Children Older Than 10 Years Phase 4
Recruiting NCT05734794 - Study of Rituximab Monotherapy on Children With New-onset Nephrotic Syndrome: A Randomized Controlled Trial Phase 3
Not yet recruiting NCT06130631 - Predictors of Steroid Response in Childhood Nephrotic Syndrome
Terminated NCT03878914 - Steroid Sensitive Nephrotic Syndrome in Children Phase 4
Recruiting NCT03786263 - CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
Recruiting NCT05772871 - The Efficacy and Safety of Prednisone Combined With Huaiqihuang Granule for Primary Nephrotic Syndrome in Children Phase 4
Recruiting NCT05505500 - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.